PhD Scientific Days 2026

Pathological and Oncological Sciences 2.

Comparison of immune-checkpoint inhibitor therapy efficacy according to the predictive marker tests, microsatellite instability (MSI) and mismatch-repair deficiency (dMMR), used for patient selection

Előadó neve

Dr. Nádorvári, Maja Lilla

Neptune code

GUUIR

Előadó munkahelye

Patológiai, Igazságügyi és Biztosítási Orvostani Intézet

Előadó telefonszáma

06202397829

Előadó e-mail címe

nadorvari.maja.lilla@semmelweis.hu

Az előadás címe

Comparison of immune-checkpoint inhibitor therapy efficacy according to the predictive marker tests, microsatellite instability (MSI) and mismatch-repair deficiency (dMMR), used for patient selection

Szerző(k) neve és munkahelye

Maja Lilla Nádorvári¹, István Kenessey¹, Judit Kocsis², György Bodoky³, László Csaba Mangel⁴, Zsuzsanna Pápai⁵, Magdolna Dank⁶, Gyöngyvér Szentmártoni⁷, Mónika Nádorvári⁸, Anikó Maráz⁹, Katalin Boér¹⁰, József Tímár¹

1: Department of Pathology, Forensic and Insurance Medicine, Semmelweis University
2: Department of Oncoradiology, Bács-Kiskun County Hospital, 6000 Kecskemét, Hungary
3: Department of Oncology, St László Teaching Hospital, Budapest, Hungary
4: Oncotherapy Institute, University of Pécs, Pécs, Hungary
5: Military Hospital Budapest, Department of Oncology
6: Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary, National Institute of Oncology
7: Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
8: Department of Oncoradiology, Jósa András Szabolcs-Szatmár-Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary
9: Department of Oncotherapy, University of Szeged, Szeged, Hungary
10: Department of Medical Oncology, Szent Margit Hospital Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Pathological and Oncological Sciences 2.

Language of the presentation

Hungarian

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Background/objectives. International guideline recommendations consider immunohistochemistry (IHC) for dMMR or molecular techniques (PCR, NGS) for MSI-high determination equal, although there are scattered reports contradicting to this presumption. Here we aimed to analyze if the efficacy of ICI (immune-checkpoint inhibitor) therapies is influenced by the diagnostic method based on patient selection.
Materials and Methods. In this multi-center retrospective analysis, we have directly compared 110 anti-PD1 immune-checkpoint inhibitor treated patients’ OS (overall survival) and PFS (progression free survival) according to the qualifying diagnostic method: four MMR protein IHC or Pentaplex MSI-PCR. 54 patients were diagnosed with MMR IHC and 56 with MSI PCR tests. 36 male and 75 female patients were involved in the study and 93 patients had colorectal cancer. The mean age of the patients was 67 years ± 15 years, and 66 ± 14 years for the colorectal part of the cohort. The follow-up was set for four years. (SE-RKEB37/2024)
Results. The Kaplan-Meier analysis did not show significant differences neither in PFS (p=0.386) nor in OS (p=0.403). This analysis was repeated for the colorectal cancer subcohort (n=62). The Kaplan-Meier analysis, did not demonstrate significant differences, neither in PFS (p=0.974) nor in OS (p=0.487). The efficacy of ICI therapies were also analyzed according to treatment lines. The OS (p=0.693) and PFS (p=0.624) did not show a significant difference in the colorectal part of the cohort, when the therapy was given in first-line setting. However, if the ICI therapies were administered in colorectal cancers as a second-or later-line treatment, both OS (p=0.011) and PFS (p=0.036) showed a significant difference in accordance with the diagnostic method.
Conclusion. Our study demonstrated that the therapeutic efficacy of the anti-PD1 antibodies in cancer patients shows a disparity whether the patients were qualified by MSI-PCR/MMR-IHC, in the whole cohort, as well as in different treatment lines and cancer types. However, there is a significant difference in therapeutic efficacy according to the diagnostic method (MSI-PCR, MMR-IHC) in later-line-treated colorectal patients. Our research showed that MSI-H status by molecular PCR test is more efficient predictive biomarker for immune-checkpoint-inhibitor therapies in colorectal cancer patients.

University

Semmelweis University

Supervisor

Prof. Dr. Tímár József

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem hagyta jóvá

Előadó

8074

Start

12:30

End

12:40